Shop Talk : Oncology Times
An abstract is unavailable.
Related Articles
FDA Advises Against Use of BioZorb Markers and BioZorb LP Markers
The FDA has announced that BioZorb Markers and BioZorb LP Markers should no longer be used.
Mechanistic and kinetic insights into transcription factor biology via acute protein depletion
Genetic loss-of-function studies have facilitated the characterization of hematopoietic transcription factors (TFs) in both normal physiology and pathological conditions. The knockout or knockdown of a…
JAK Inhibitors Remain the Gold Standard in Myelofibrosis
Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.
Navigating Adverse Effects of JAK Inhibitors in Myeloproliferative Neoplasms
Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
DE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.
Prospective Registration Study for Establishing Minimal… : Spine
Despite its proven usefulness in degenerative spinal diseases and deformities, the MCID remains unexplored regarding surgery for spinal metastases. Patients and Methods. This study included…
FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Ph+ Chronic-Phase Chronic Myeloid Leukemia
The FDA has granted accelerated approval to asciminib for newly diagnosed, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.
IASLC Academy | IASLC
The IASLC Academy is a prestigious program geared toward early-career physicians worldwide who aspire to pursue academic careers in thoracic oncology.
Interpreting IDeate-Lung02 Trial Outcomes
Joshua K. Sabari, MD, discusses the efficacy outcomes from the Ideate-Lung02 trial, noting the 52.4% ORR, 5.9-month median DOR, and 12.2-month OS and emphasizing that…